Avia Pharma has today completed the acquisition of Unimedic’s Vitamin D oil. “The acquisition is in line with Avia Pharma’s strategy to own more products and will complement our existing portfolio”, says Jacob Calmvik, CEO of Avia Pharma. For further information, please contact Jacob Calmvik, CEO Avia Pharma, jacob.calmvik@aviapharma.se, +46 703
Avia Pharma has today completed the acquisition of Allergika Pharma GmbH. The company has a turnover of close to 15 million EUR and is placed in Wolfratshausen, near Munich. Allergika is a German pharmaceutical company focused on the allergy market. It sells both dermatology products and encasing under its own
Avia Pharma has today completed the acquisition of Decem Pharma. Decem Pharma is a Finish pharmaceutical company with its own brands with strong market positions, such as Magnecit and Otocur. The acquisition of Decem Pharma is Avia Pharma’s first acquisition outside of Sweden and part of its strategy to build
Avia Pharma are happy to announce that we have further deepen our relationship with Perrigo to include Dentosal, a much appreciated tooth paste, on the Nordic market.
The pharmaceutical company Avia Pharma has acquired the Swedish pharmaceutical company Pharmaprim, with a product portfolio consisting of drugs in urology, rheumatology and endocrinology.
On December 31, 2019, Avia Pharma acquired the rights to ACO Karbamid and ACO Glycerol from Perrigo.
Following a strong sales increase in the current portfolio, Viiral AS have trusted Avia Pharma to launch Viiral on the Nordic market.
With a strong foot print in women’s health Avia Pharma are trusted to launch Femarelle in Finland.
Following a strong sales increase in the current portfolio, Avia Pharma and Perrigo have deepened the relationship to also include Vectavir®, Vectatone®, Oralmedic® and Predictor®.
Avia Pharma has signed a long-term license agreement with Endoceutics for the Nordic commercial rights to Intrarosa®.
Avia Pharma appoints Mattias Wik as Business Unit Director Oncology/Urology.
Currently there are two Vitamin D drops being sold on the Swedish market. ACO Vitamin D drops does not contain palm oil but the competing product does.
Following a very strong sales increase for all products, Omega Pharma and Avia Pharma has decided to expand their co-operation.
Avia Pharma appoints Marie Wikman as Business Unit Director OTC.
Avia Pharma and Dr Pfleger have entered into a long-term license agreement for Spasmex (Trospium) and Vagitin (Nystatin). The license for Spasmex covers Sweden and Norway and the license for Vagitin covers all Nordic countries.
The Swedish MPA has approved a new formulation of ACO Vitamin D without palm oil.
Avia Pharma has developed a more contemporary package for Duroferon on the Swedish market. The new design affects the 100-tablet blister, the 200-tablet blister and the 100-tablet plastic container.
Avia Pharma appoints Jonas Karlander as CFO.
The new “Kloka Listan” from SLL has updated its recommendation for iron supplements. It previously stated, incorrectly, that Niferex had fewer adverse events than Duroferon.
Avia Pharma has entered into an in-licensing agreement with Omega Pharma for the following products; Duroferon, Ferro Duretter, Minifom, D-vitamin Olja ACO, D-vitamin Vatten ACO, Dunmedic Vitamin D-olja and Nix.Under the agreement Avia Pharma will handle all commercial aspects of the products.
Avia Pharma AB
Svärdvägen 3B
S-182 33 Danderyd
Sweden